|Bid||81.21 x 1800|
|Ask||81.24 x 1200|
|Day's Range||81.09 - 82.49|
|52 Week Range||79.13 - 106.74|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||120.29|
Myovant's plan to control heavy menstrual bleeding, how President Trump's executive order on kidney treatments could help a San Francisco company and more in our Health Care Digest.
SAN RAFAEL, Calif. , July 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMRN had net inflows of $7.05 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN): BioMarin Pharmaceutical Inc., a biotechnology company, develops and...
JP Morgan’s Cory Kasimov is making bullish bets on these two gene therapy stocks. This is an area with the potential to completely transform the healthcare landscape. It involves making changes to DNA to help treat, or potentially even cure, a disease. Although it is still early days, there are an estimated 10,000 diseases caused by a single mutation that can theoretically be corrected with a targeted gene therapy. These are known as monogenic diseases. “Though relatively rare, they affect millions of people worldwide” writes the World Health Organization, adding that in Canada monogenic diseases may account for up to 40% of the work of hospital based paediatric practice (Scriver, 1995).Here we take a closer look at two gene therapy stocks JP Morgan’s Kasimov believes is primed to outperform. Note that both these stocks also score a ‘Strong Buy’ consensus from top-performing analysts. That’s based on all the ratings received by each stock over the last three months. Let’s take a closer look now: BioMarin (BMRN)BioMarin is a world leader in developing innovative therapeutics for rare genetic diseases. “We believe BioMarin’s depth and breadth of orphan disease assets present a unique opportunity in biotech” cheers Kasimov. Indeed, the company has seven products on the market, and a growing product pipeline of multiple clinical and preclinical candidates. Excitingly, this includes valrox gene therapy for the treatment of Hemophilia A. This genetic disease is caused by the deficiency of clotting factor VIII. It is the most common type of hemophilia, with an estimated 90,000 patients in the territories where BioMarin operates.Currently the standard of care for severe hemophilia A patients is intravenous infusions three times a week. However many patients still experience spontaneous bleeding events- which can prove fatal. In contrast, gene therapy has the promise of delivering, in as little as a single administration, the missing gene needed to produce factor VIII. BioMarin has now revealed plans to submit valrox for regulatory approval in US/EU in 4Q19. Kasimov calls the news “an incremental positive that could serve to help firmly establish valrox in the commercial setting well ahead of any potential competitors.”He sees the stock as ‘undervalued’ at current levels and writes: “BMRN remains a high conviction long-term idea between its orphan-focused, diversified base business (>$1B in sales), growing commercial portfolio, and potentially disruptive late-stage pipeline.” Kasimov has a $133 price target on the stock (65% upside potential).In total, eleven top analysts have published buy ratings on the stock in the last three months. So no hold or sell ratings here. Meanwhile the $133 average analyst price target suggests sizable upside potential of 60% lies ahead. View BMRN Price Target & Analyst Ratings Detail Bluebird Bio (BLUE)Bluebird Bio is a clinical-stage company that, like BioMarin, is developing potentially transformative gene therapies for severe genetic and rare diseases. In particular, the company has just released updated results for LentiGlobin- a potential treatment and cure for sickle cell disease (SCD). Investors are keeping a close eye on the sickle cell opportunity, as this is a severe life-shortening blood disorder affecting around 110,000 patients in the US. Kasimov describes the latest results as ‘consistent’ and ‘incredibly profound’, adding that “the SCD data, in particular, reaffirms our prevailing view that… LentiGlobin is going to be exceedingly hard to beat by earlier-stage competition.” Bluebird expects filing and approval for LentiGlobin for SCD to take place in 2022.At the same time, it’s the company’s broad focus that really sets BLUE apart. “One particularly attractive yet underappreciated aspect of Bluebird is all the different technologies it has at its disposal”, says Kasimov. For BLUE that means using the right tools/ combinations to effectively design novel therapeutic- be it gene therapy, gene therapy, CAR T capabilities or even gene editing. For example, the company has also demonstrated encouraging initial data for bb2121, a CAR-T therapy for the potential treatment of multiple myeloma, that it is developing with Celgene (CELG). Net-net “We remain intrigued by an innovative company that has the potential to go 4-for-4 with its lead assets and has a multitude of tools in the shed (an anti-pure-play) to fuel the pipeline for a long time to come” says the analyst. He has a Street-high price target on BLUE of $195 (52% upside potential), and concludes: “In our opinion, BLUE is well positioned for long-term success.” Overall, top analysts agree with this upbeat outlook. Three out of four analysts rate the stock a ‘buy.’ We can also see that the $153 average analyst price target indicates upside potential of 19%.View BLUE Price Target & Analyst Ratings DetailView other top biotech stock ideas with the Top Analysts' Stocks tool
BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.
SAN RAFAEL, Calif. , July 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical ...
Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Potential 1st Marketing Application for a Gene Therapy Product in Any Type of Hemophilia to be Reviewed by Health Authorities Late-Breaking Abstract at the 27th International Society on Thrombosis and ...
Facebook makes more profit per employee than any other tech company on the Fortune 500: A whopping $634,694 per year. Here's how that compares with other major tech employers like Google, Apple and Cisco.
Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let's study the drivers and risks for both these rare disease players in greater detail.
Morningstar's U.S. Healthcare Index has increased 1% quarter to date through June 21 and 9% year to date, trailing the market over both intervals (Exhibit 1) amid concern around healthcare pricing pressures.
SAN RAFAEL, Calif., June 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and principal investigator for the valoctocogene roxaparvovec Phase 1/2 study (BMN 270-201) and the Phase 3 study (BMN 270-301) will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress being held July 6-10, 2019 in Melbourne, Australia. More than 5,000 experts from over 90 countries in the field will convene at the Melbourne Convention Exhibition Centre (MCEC) to present the latest basic, translational and clinical research and discuss the diagnostic and therapeutic advances in bleeding and clotting disorders.
Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.
Recent news from a leading gene therapy company highlights the risks, but the charts suggest ample room to the upside for biotech stocks.
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
European Commission Approval Triggers $15 Million Payment BioMarin Entitled to Earn Mid-Single Digit Royalties on Future Sales SAN RAFAEL, Calif. , June 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical ...
Bitcoin trading was active again Monday amid a solid gain for the Nasdaq. The tech-laden index was helped by strength in software and biotech stocks.
Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.